how are compounding pharmacies still selling tirzepatide Oral Hallandale is ceasing all tirzepatide

Orforglipron (Foundayo), approved April 1, 2026 for obesity or overweight with a weight-related condition

It should be stressed that the TIP peptide is a specific and direct activator of ENaC, unlike other used indirect activators, such as aldosterone, the latter of which can also exert ENaC-independent effects, which may chronically affect vascular function through the paracrine release of histamine (Schjerning et al., 2013)

While many patients can reach their weight-loss goals within six months to a year, others need up to two years, and some require long-term GLP-1 maintenance due to the chronic nature of their condition

That is a conversation to have with your GP or a specialist haematologist, not a reason to add a private injection on top of an NHS schedule without telling either provider